Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.50 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | LPL | P06858 | 8/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26011862 | 0.87 | AAK1 (0.45) | AAK1GSK3AGSK3BLPLLIPG | |
| SCHEMBL251502 | 0.85 | ALPL (0.45) | AAK1GSK3AGSK3BLPLLIPG | |
| SCHEMBL20191051 | 0.85 | AAK1 (0.53) | AAK1GSK3AGSK3BLPLLIPG | |
| SCHEMBL613434 | 0.84 | AAK1 (0.46) | AAK1GSK3AGSK3BLPLLIPG | |
| SCHEMBL26013257 | 0.84 | AAK1 (0.50) | AAK1GSK3AGSK3BLPLLIPG | |
| SCHEMBL26464702 | 0.83 | AAK1 (0.55) | AAK1GSK3AGSK3BLPLLIPG | |
| SCHEMBL26464168 | 0.82 | AAK1 (0.51) | AAK1GSK3AGSK3BLPLLIPG | |
| SCHEMBL462679 | 0.82 | AAK1 (0.47) | AAK1GSK3AGSK3BLPLLIPG | |
| SCHEMBL27314904 | 0.82 | AAK1 (0.45) | AAK1GSK3AGSK3BLPLLIPG | |
| SCHEMBL30864874 | 0.82 | AAK1 (0.45) | AAK1GSK3AGSK3BLPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767325-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| EP-2545055-B1 | Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-09 | — | — | EP | disclosed |
| US-8859543-B2 | Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-14 | — | — | US | disclosed |
| US-8859543-B2 | Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-14 | — | — | US | disclosed |
| US-8859543-B2 | Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-14 | — | — | US | disclosed |
| US-20120329792-A1 | IMIDAZO[1,2-a]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | JANSSEN PHARMACEUTICA NV | 2012-12-27 | — | — | US | disclosed |
| US-20120329792-A1 | IMIDAZO[1,2-a]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | JANSSEN PHARMACEUTICA NV | 2012-12-27 | — | — | US | disclosed |
| US-20120329792-A1 | IMIDAZO[1,2-a]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | JANSSEN PHARMACEUTICA NV | 2012-12-27 | — | — | US | disclosed |
| WO-2011110545-A1 | IMIDAZO [1, 2 -A] PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329792-A1 | IMIDAZO[1,2-a]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | PDE12, PDE10A, PDE5A | AAK1 957/4885GSK3A 1357/4885GSK3B 1651/4885 |
| US-11767325-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators | SCN1A, SCN2A, SCN5A | AAK1 1453/4885GSK3A 2812/4885GSK3B 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.